Deals Shaping The Medical Industry, April 2015
Executive Summary
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced March 2015.
You may also be interested in...
France’s Gemme Claims A Victory With Price-Cut Reversal
French generics industry association Gemme has claimed a major victory in shifting the country’s policy on generic price cuts, after the government announced a moratorium on price reductions as well as targeted price increases for certain key locally-produced generics.
Pfizer Quietly Chalks Up Another $2bn Year For Biosimilars
Despite annual sales that topped out at more than $2bn, Pfizer remains tight-lipped about its biosimilars interests as it looks towards a US launch this year of its Abrilada rival to Humira.
Australia Becomes First Country To Regulate Psilocybin & MDMA As Medicines
The Therapeutic Goods Administration said its decision to down-schedule two psychedelic substances to controlled drug status followed extensive public consultation, a report from an independent expert panel, and advice from the Advisory Committee on Medicines Scheduling.